Genomtec is selling at 7.44 as of the 2nd of December 2024; that is 4.20% up since the beginning of the trading day. The stock's lowest day price was 7.15. Genomtec has hardly any chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Equity ratings for Genomtec SA are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 13th of December 2022 and ending today, the 2nd of December 2024. Click here to learn more.
Although Genomtec's alpha and beta are two of the key measurements used to evaluate Genomtec's performance over the market, the standard measures of volatility play an important role as well.
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Genomtec stock to make a market-neutral strategy. Peer analysis of Genomtec could also be used in its relative valuation, which is a method of valuing Genomtec by comparing valuation metrics with similar companies.
When running Genomtec's price analysis, check to measure Genomtec's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genomtec is operating at the current time. Most of Genomtec's value examination focuses on studying past and present price action to predict the probability of Genomtec's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genomtec's price. Additionally, you may evaluate how the addition of Genomtec to your portfolios can decrease your overall portfolio volatility.